Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

AIA Group Ltd raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 10.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,411 shares of the biotechnology company’s stock ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Through various recent evolutions, the economic situation of the pharmaceutical companies operating in France become increasingly challenging.

Expert Rev Ophthalmol. 2009;4(2):163-171. Intravitreal triamcinolone acetonide may be combined with photocoagulation. In a RCT, 111 patients were randomized to receive photocoagulation alone, IVTA ...